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Deﬁciencies in the human DNA repair gene WRN are the cause of Werner syndrome,  a rare auto-
somal recessive disorder characterized by premature aging and a predisposition to cancer.  This study 
evaluated the association of WRN Leu1074Phe (rs1801195),  a common missense single nucleotide poly-
morphism in WRN,  with prostate cancer susceptibility in Chinese subjects.  One hundred and forty-
seven prostate cancer patients and 111 male cancer-free control subjects from 3 university hospitals in 
China were included.  Blood samples were obtained from each subject,  and the single nucleotide poly-
morphism WRN Leu1074Phe was genotyped by using a Snapshot assay.  The results showed that WRN 
Leu1074Phe was associated with the risk of prostate cancer in Chinese men and that the TG/GG geno-
type displayed a decreased prevalence of prostate cancer compared with the TT genotype (OR＝0.58,  
95ｵCI: 0.35-0.97,  p＝0.039).  Through stratiﬁed analysis,  more signiﬁcant associations were revealed 
for the TG/GG genotype in the subgroup with diagnosis age ｦ 72 yr (OR＝0.27,  95ｵCI: 0.12-0.61,  p
＝0.002) and in patients with localized diseases (OR＝0.36,  95ｵCI: 0.19-0.70,  p＝0.003).  However,  no 
statistically signiﬁcant diﬀerence was found in the subgroup with age ＞72 yr or in patients with 
advanced diseases.  We concluded that the genetic variant Leu1074Phe in the DNA repair gene WRN 
might play a role in the risk of prostate cancer in Chinese subjects.  
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eing the most common malignancy among men,  
prostate cancer (PCa) constitutes a major health 
problem in developed countries.  The incidence of 
prostate cancer in China is low [1].  However,  along 
with lifestyle changes and the process of westerniza-
tion,  the morbidity of prostate cancer has increased 
dramatically in recent years,  and it is becoming a 
great health burden in China [2,  3].  
　 Accumulating evidence suggests that genetics play 
an important role in the etiology of prostate cancer 
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[4,  5].  Through many large-scale and genome-wide 
genetic studies,  many single nucleotide polymor-
phisms (SNPs) have been found to be associated with 
an increased risk of prostate cancer,  yet these SNPs 
only had moderate eﬀects individually,  and the 
responsible genes remain largely unidentiﬁed [6,  7].
　 The DNA repair gene WRN is located at chromo-
some 8p11-12.  WRN protein is an important member 
of the RecQ helicase family,  which is involved in 
multiple DNA repair pathways,  protecting the genome 
from incorrect recombination during mitosis and main-
taining its stability [8].  Deﬁciencies in the human 
RecQ helicase gene WRN are the cause of Werner 
syndrome,  a rare autosomal recessive disorder char-
acterized by premature aging and a predisposition to 
cancer.  Since mutations in the gene WRN lead to 
accelerated aging and cancer susceptibility,  it has 
been reasoned that polymorphisms in the gene WRN 
may also be associated with age-related pathologies,  
including a high incidence of cancer.  
　 WRN Leu1074Phe (rs1801195),  one of the common 
missense SNPs in the gene WRN [9],  usually mani-
fests a G to T variation and leads to a protein varia-
tion of 1074Leu to Phe.  The WRN Leu1074Phe 
polymorphism located in the C-terminus of WRN.  The 
variant protein 1074Phe/Phe was reported to exhibit 
a small decrease in helicase and exonuclease activities 
relative to the wild-type protein [10].  In previous 
studies,  WRN Leu1074Phe had been found to be 
associated with many diseases,  including breast can-
cer [9,  11].
　 Prostate cancer manifests an obvious increase in 
morbidity along with aging,  and its relationship with 
the Werner syndrome gene WRN has never been 
investigated.  In the present study,  we discuss the 
association of the polymorphism WRN Leu1074Phe 
with the risk of PCa in Chinese men for the ﬁrst time.
Materials and Methods
　 Study subjects. The subjects studied came 
from 2 cities in China: Beijing,  in the north of China 
and Hangzhou,  in the south of China.  Participants 
were recruited from 2 university hospitals in Beijing 
and one university hospital in Hangzhou between 
January 2009 and June 2010.  The inclusion criterion 
for cases was pathologically veriﬁed adenocarcinoma 
of the prostate,  whether newly diagnosed or not.  An 
informed consent form was signed by both the physi-
cian and the recruited patient before a 2-ml blood 
sample was obtained from each patient.  A question-
naire,  which included questions regarding prostate 
cancer family history,  diet (frequencies of eating 
meats,  ﬁsh,  seafoods,  milk,  vegetables,  fruits,  beans 
and frumentum in daily life),  smoking status (never/
ever,  years of smoking history and cigarettes/day),  
drinking status (never/ever,  years of drinking history,  
grams of alcohol/day) and clinical information,  such as 
age,  Gleason score and prostate-speciﬁc antigen 
(PSA) level at the time of diagnosis,  tumor-node-
metastasis (TNM) staging,  pathology,  treatment 
(radical prostatectomy,  hormone therapy,  radiation 
therapy,  combined therapy,  etc. ) and current situa-
tion (survival,  death,  relapse,  metastasis,  etc. ) was 
also sent to each eligible case patient.  TNM staging 
was determined after an operation or based on imaging 
modalities and biopsy result.  
　 In total,  166 prostate cancer patients were invited 
to participate; of those,  147 (88.6ｵ) agreed to par-
ticipate by donating a blood sample and/or answering 
the questionnaire.  The patients were classiﬁed 
according to localized PCa — T1-2 and N0/NX,  
M0/MX,  Gleason sum 2-7,  and PSA level less than 
50ng/ml or advanced PCa — T3/4 or N＋ or M＋ or 
Gleason sum 8-10 or PSA level greater than 50ng/
ml.
　 The control subjects were male cancer-free 
patients or healthy men.  They were randomly selected 
from the above-mentioned 3 hospitals during the 
recruitment stage and frequency matched according to 
the expected age distribution (within 5 years) and 
geographic origin of the case patients.  The PSA value 
was also checked for each control subject as a screen-
ing marker,  and only those with a PSA value ＜4ng/
ml were included.  After informed consent was 
obtained from the control subjects,  a 2-ml blood sam-
ple was obtained and a questionnaire was administered 
to each subject just as for the case patients.  Of the 
137 randomly selected control subjects invited,  111 
(81.0ｵ) agreed to participate by contributing a blood 
donation and/or completing the questionnaire.
　 All procedures were carried out with the adequate 
understanding and written consent of each subject.  
The study was also approved by ethics committee of 
each hospital.
　 Blood samples and DNA extraction. Strict 
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procedures were followed for blood handling and 
transport to ensure consistency.  A 2-ml sample of 
donated blood was obtained from each participant and 
it remained at room temperature for no more than 6 
hours.  The blood samples were then stored at －20℃ 
and transported to our laboratory in Peking 
University Peopleʼs Hospital,  Beijing,  using a dry ice 
box within 1 month.  After the blood samples arrived 
at the laboratory,  genomic DNA was extracted using 
the phenol-chloroform method as soon as possible.  
Overall,  100ｵ of the samples had suﬃcient DNA for 
the study.
　 Genotyping. Genotyping was conducted by 
Yingjun Biotechnology Co.,  Ltd in Shanghai,  China.  
A method adapted to the ABI SNaPshot® multiplex 
system was used to genotype the polymorphism WRN 
Leu1074Phe as well as 6 other SNPs (not mentioned 
in this paper).
　 Multiplex PCR (ﬁrst PCR). Multiplex PCR 
ampliﬁcation was carried out on an ABI 9700 
Thermocycler using 1µl genomic DNA (10-50ng) as a 
template,  1µl 10×PCR buﬀer,  0.8µl dNTPs 
(2.5mM each),  0.05µl rTaq (5U/µl),  1.4µl ﬁrst 
primer mix and water to a ﬁnal reaction volume of 
10µl.  The program used was an initial denaturation 
step of 94℃ for 3 min followed by 32 cycles of 94℃ 
for 30sec,  60℃ for 30sec and 72℃ for 30sec.  The 
ﬁnal extension step was carried out for 7min at 72℃.  
The ﬁrst PCR primers for WRN Leu1074Phe were:  
upper primer 5 -ʼAAACGGTGTAGGAGTCTGC CT-3,ʼ  
and lower primer 5ʼ-TTCATTTTACTTGTGAGA 
GGCCT-3ʼ.  
　 The PCR products were checked on a 2ｵ agarose 
gel.  To avoid participation in a subsequent primer 
extension reaction,  the primers and unincorporated 
dNTPs of the preliminary PCR reaction were 
removed before genotyping: 5µl of PCR product was 
incubated with 2 units of ExoSAP for 60min at 37℃,  
followed by 15min at 75℃ for enzyme inactivation.
　 SNaPshotTM reaction. The typing PCR 
(second PCR) primer used for WRN Leu1074Phe was 
5 ʼ -TTTTTTTTTTTTTTTTTTTTTTTTT 
CTAATGAAGAATTGTG TCCAAAGAAGTT-3ʼ.  
Noting that all the primers were used simultaneously 
for seven SNP targets,  many T residues were 
attached to the typing primer of WRN Leu1074Phe to 
discriminate it from the other targets.  The single 
typing primer was used for typing a single SNP geno-
type with ddNTP end-labeling.  
　 SNaPshot reactions were carried out using 1.5µl 
puriﬁed ﬁrst PCR products as a template,  typing 
primer mix,  2.5µl of SNaPshot multiplex ready reac-
tion mix (ABI),  and water to a ﬁnal reaction volume of 
5µl.  Reactions were carried out in the ABI 9700 
Thermocycler at 96℃ for 10sec,  50℃ for 5sec and 
60℃ for 30sec,  and repeated for a total of 30 cycles.  
Following cycling,  the samples were treated with 1 U 
of shrimp alkaline phosphatase (SAP) at 37℃ for 1h 
and heat-inactivated at 72℃ for 15min.  
　 In an ABI optical plate,  9µl of HI-DI formamide,  
0.5µl of Genescan 120 LIZ size standard (ABI) and 
0.5µl of the reaction mixture were combined,  dena-
tured at 95℃ for 5min,  and immediately placed on ice 
for 2min.  Samples were then loaded on the ABI 
PRISM 3100 Genetic Analyzer and analyzed using the 
Genescan (version 3.1) software.
　 Statistical analysis. Data were given as means 
± standard deviation (SD) for variables with normal 
distribution,  and otherwise as medians.  A test for 
Hardy-Weinberg equilibrium was performed among the 
control subjects with the use of Chi-squared tests or 
the exact test if any of the cell counts were ＜5.  The 
diﬀerences of allele and genotype frequencies between 
case patients and control individuals were analyzed 
using Pearsonʼs χ2 test.  Genotype data were analyzed 
with the homozygotes of the common allele as the 
reference group.  Odds ratios (ORs),  95ｵ conﬁden-
tial intervals (CIs) and corresponding P values for the 
association between prostate cancer risk and geno-
types (or alleles) were calculated using logistic 
regression analysis by comparing the genotypes 
between case patients and control subjects.  In addi-
tion,  we stratiﬁed our analyses by age at diagnosis 
(＞72 and ｦ72 yrs),  and by aggressiveness of the 
disease (localized and advanced cases,  as described 
above).  For all analyses,  genetic eﬀects were adjusted 
for age (at time of diagnosis for case subjects and at 
time of ascertainment for controls),  smoking status and 
alcohol use.  All statistical tests were performed using 
SPSS program version 11.5 for Windows.  A p value 
of ＜0.05 was considered statistically signiﬁcant 
(two-tailed).
Results
　 The clinical characteristics of the study partici-
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pants are presented in Table 1.  The mean ages (age at 
diagnosis for case patients and age at inclusion for 
control subjects) for case patients and control subjects 
were 71.8 and 70.2 years,  respectively.  PSA values 
of control subjects were all below 4ng/ml,  with a 
median value of 1.21ng/ml.  
　 Subjects were recruited from 2 separate areas of 
China.  Considering the huge total area of the nation 
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Table 1　 Clinical and demographic characteristics of the subjects
Characteristic
Advanced 
PCa
(n＝91)
Localized 
PCa
(n＝56)
All Case 
Subjects
(n＝147)
Control 
Subjects
(n＝111)
P value＊
Age (yr) 
Mean age 72.2±9.1 71.0±9.8 71.8±9.3 70.2±9.8 0.19
Age at diagnosis [n (％)]
　ｦ72 37 (40.7) 31 (55.4) 68 (46.3) 51 (45.9) 0.96
　＞72 54 (59.3) 25 (44.6) 79 (53.7) 60 (54.1)
Smoking status
　Never 57 (62.6) 34 (60.7) 91 (61.9) 65 (58.6) 0.59
　Ever 34 (37.4) 22 (39.3) 56 (38.1) 46 (41.4)
Drinking status
　Never 67 (73.6) 42 (75.0) 109 (74.1) 81 (73.0) 0.83
　Ever 24 (26.4) 14 (25.0) 38 (25.9) 30 (27.0)
PSA level [n (％)]
No. of subjects 90 52 142 109
　ｦ4.0ng/ml 2 (2.2) 3 (5.8) 5 (3.5) 109 (100.0)
　4.1-9.9ng/ml 5 (5.6) 17 (32.7) 22 (15.5)   0
　10.0-19.9ng/ml 10 (11.1) 22 (42.3) 32 (22.5)   0
　20.0-49.9ng/ml 21 (23.3) 10 (19.2) 31 (21.8)   0
　50.0-99.9ng/ml 13 (14.4)  0 13 (9.2)   0
　ｧ100.0ng/ml 39 (43.3)  0 39 (27.5)   0
Missing data  1  4   5   2
Tumor stage [n (％)]
No. of subjects 90 55 145
　T1 7 (7.8) 19 (34.5) 26 (17.9)
　T2 25 (27.8) 36 (65.5) 61 (42.1)
　T3 44 (48.9)  0 44 (30.3)
　T4 14 (15.6)  0 14 (9.7)
Missing data  1  1   2
Nodal stage [n (％)]
No.  of subjects 79 56 135
　N0 53 (67.1)  56 (100.0) 109 (80.7)
　N1 26 (32.9)  0 26 (19.3)
Could not be assessed 12  0  12
Metastasis stage [n (％)] (％)
No.  of subjects 90 55 145
　M0 46 (51.1)  55 (100.0) 101 (69.7)
　M1 44 (48.9)  0 44 (30.3)
Could not be assessed  1  1   2
Gleason score [n (％)]
No.  of subjects 73 52 125
　2-6  8 (11.0) 19 (36.5) 27 (21.6)
　7 18 (24.7) 33 (63.5) 51 (40.8)
　8-10 47 (64.4)  0 47 (37.6)
Missing data 18  4  22
＊Calculated based on data from control and all case subjects
of China,  the genetic backgrounds of these 2 areas are 
of great interest.  We compared the genotype frequen-
cies of WRN Leu1074Phe between the 2 populations 
but found no signiﬁcant diﬀerences (Table 2).  We 
therefore combined data from the 2 populations in the 
following statistical calculations.
　 The allele and genotype frequencies of WRN 
Leu1074Phe among case and control subjects are 
listed in Table 3.  The results of allelic and genotypic 
tests are also shown.  The genotype frequency did not 
deviate statistically significantly from Hardy-
Weinberg equilibrium (pｧ0.05).  
　 Prostate cancer subjects had a lower proportion of 
the G allele (32.3ｵ vs.  38.3ｵ) and TG/GG genotype 
(53.1ｵ vs.  65.8ｵ) than control subjects.  The TG/
GG genotype was supposed to be a protective genotype 
with decreased risk for prostate cancer in the present 
study.  The estimated odds ratio (OR) for carriers 
with the TG/GG genotype was 0.58 (95ｵCI: 0.35-
0.97,  p＝0.039) compared with the TT genotype,  
after being adjusted for age,  smoking status and 
alcohol use.  However,  the diﬀerence between the G 
and T alleles was not signiﬁcant (OR＝0.76,  95ｵ
CI: 0.52-1.09,  p＝0.138).
　 In the subsequent stratiﬁed analyses,  we chose a 
diagnosis age of 72 as the dividing line so there would 
be equal numbers of older and younger cases.  As 
shown in Table 4,  more signiﬁcant associations of the 
TG/GG genotype (OR＝0.27,  95ｵCI: 0.12-0.61,  p
＝0.002) were found in the early onset subgroup.  The 
G allele also manifested a signiﬁcant association with 
PCa in this subgroup (OR＝0.44,  95ｵCI: 0.25-
0.76,  p＝0.004).  However,  no statistically signiﬁcant 
association of both risk genotype and allele was found 
in the subgroup with diagnosis age ＞72.  
Interestingly,  through stratiﬁcation by aggressive-
ness,  the decreased risk for carriers of the G allele 
(OR＝0.49,  95ｵCI: 0.29-0.82,  p＝0.007) and TG/
GG genotype (OR＝0.36,  95ｵCI: 0.19-0.70,  p＝
0.003) was accentuated in patients with localized dis-
ease,  but vanished in those with advanced disease 
(Table 5).  
　 Table 6 shows that the genotype distribution of 
WRN Leu1074Phe was not signiﬁcantly associated 
with a list of clinical characteristics of prostate cancer 
such as Gleason score,  serum PSA level at diagnosis,  
or age at diagnosis.  Interaction analysis between the 
polymorphism and other potential risk factors,  such as 
smoking and drinking status,  also had negative results.  
However,  subjects with localized disease seem to have 
a higher distribution of risk genotype TT compared 
with patients with advanced disease (p＝0.023).
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Table 2　 Comparison of genotype frequencies of WRN Leu1074Phe between subjects from Hangzhou and Beijing
Control Cases
Area Hangzhou Beijing P value Hangzhou Beijing P value
Genotype n＝40 n＝71 0.86 n＝57 n＝90 0.27
TT 15 (37.5) 23 (32.4) 31 (54.4) 38 (42.2)
GT 21 (52.5) 40 (56.3) 19 (33.3) 42 (46.7)
GG  4 (10.0)  8 (11.3)  7 (12.3) 10 (11.1)
Table 3　 Association of WRN Leu1074Phe with prostate cancer susceptibility 
SNP Gene
Genotype 
or Allele
Controls (％)
n＝111
Cases (％)
n＝147
Crude OR
(95％CI)
P 
value
Adjusted OR†
(95％CI)
P 
value
Leu1074Phe 
(rs1801195)
WRN TT  38 (34.2)  69 (46.9) 1.00 (Ref.) 1.00 (Ref.)
TG  61 (55.0)  61 (41.5) 0.55 (0.32-0.94) 0.028 0.55 (0.32-0.94) 0.029
GG  12 (10.8)  17 (11.6) 0.78 (0.34-1.80) 0.56 0.74 (0.32-1.72) 0.49
TG or GG  73 (65.8)  78 (53.1) 0.59 (0.35-0.98) 0.041 0.58 (0.35-0.97) 0.039
T 137 (61.7) 199 (67.7) 1.00 (Ref.) 1.00 (Ref.)
G  85 (38.3)  95 (32.3) 0.77 (0.53-1.11) 0.16 0.76 (0.52-1.09) 0.14
†Adjusted for age,  smoking status and alcohol use in a logistic regression model
Discussion
　 In the present case‒control study,  we studied the 
eﬀect of WRN Leu1074Phe,  a missense SNP in DNA 
repair gene WRN,  on the risk of prostate cancer 
among 147 prostate cancer patients and 111 cancer-
free controls,  and found it to be signiﬁcantly associ-
ated with prostate cancer susceptibility in Chinese 
subjects.  To our knowledge,  this is the ﬁrst study to 
reveal the association between DNA repair gene WRN 
and the risk of prostate cancer.  Moreover,  in subse-
quent stratiﬁed analysis,  we observed statistically 
more signiﬁcant associations in the subset of cases 
with localized disease and in case subjects with a 
diagnosis age ｦ72 yr.  These ﬁndings suggested that 
the genetic variant WRN Leu1074Phe might play a 
role in prostate cancer development in Chinese men.
　 Previous studies on the gene WRN have identiﬁed 
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Table 6　 Association of WRN Leu1074Phe with clinical characteristics 
WRN 
Leu1074Phe
Aggressiveness of 
disease- no.  (％)
Gleason score [n (％)]
PSA level at 
diagnosis
Age at 
diagnosis
Smoking status Drinking status
Localized advanced 2-6 7 8-10 Median 
(ng/ml)
Mean (yr) Never Ever Never Ever
No. of subjects 56 91 27 51 47 n＝142‡ n＝147 156 102 190 68
Reference: TT 33 (58.9) 36 (39.6) 18 (66.7) 22 (43.1) 19 (40.4) 25.0 
(n＝66)
70.8 
(n＝69) 60 (38.5) 47 (46.1)  79 (41.6) 28 (41.2)
Association: TG＋GG 23 (41.1) 55 (60.4)  9 (33.3) 29 (56.9) 28 (59.6) 34.2 
(n＝76)
72.7 
(n＝78) 96 (61.5) 55 (53.9) 111 (58.4) 40 (58.8)
P value 0.023 0.070† 0.20 0.23 0.23 0.95
†Calculated by linear association; ‡Data of 5 cases missed
Table 5　 WRN Leu1074Phe genotype and allele frequencies [n (％)] and adjusted OR stratiﬁed by aggressiveness 
Genotype 
or Allele
Controls
(n＝111)
Localized 
cases
(n＝56)
Adjusted OR† 
(95％CI)
P 
value
Controls
(n＝111)
Advanced 
cases
(n＝91)
Adjusted OR† 
(95％CI)
P 
value
TT  38 (34.2) 33 (58.9) 1.00  38 (34.2)  36 (39.6) 1.00
TG  61 (55.0) 20 (35.7) 0.38 (0.19-0.76) 0.006  61 (55.0)  41 (45.1) 0.73 (0.40-1.33) 0.31
GG  12 (10.8)  3 ( 5.4) 0.29 (0.075-1.11) 0.071  12 (10.8)  14 (15.4) 1.19 (0.48-2.94) 0.71
TG＋GG  73 (65.8) 23 (41.1) 0.36 (0.19-0.70) 0.003  73 (65.8)  55 (60.4) 0.81 (0.45-1.45) 0.47
T 137 (61.7) 86 (76.8) 1.00 137 (61.7) 113 (62.1) 1.00
G  85 (38.3) 26 (23.2) 0.49 (0.29-0.82) 0.007  85 (38.3)  69 (37.9) 0.98 (0.65-1.47) 0.92
†Adjusted for age,  smoking status and alcohol use in a logistic regression model
Table 4　 WRN Leu1074Phe genotype and allele frequencies [n (％)] and adjusted OR stratiﬁed by age at diagnosis 
Genotype 
or Allele
Age at diagnosisｦ72 Age at diagnosis＞72
Controls
(n＝51)
Cases
(n＝68)
Adjusted OR†
(95％CI)
P 
value
Controls
(n＝60)
Cases
(n＝79)
Adjusted OR† 
(95％CI)
P 
value
TT 13 (25.5)  37 (54.4) 1.00 25 (41.7) 32 (40.5) 1.00
TG 32 (62.7)  28 (41.2) 0.29 (0.13-0.66) 0.003 29 (48.3) 33 (41.8) 0.95 (0.46-2.00) 0.90
GG  6 (11.8)   3 ( 4.4) 0.18 (0.039-0.88) 0.034  6 (10.0) 14 (17.7) 0.53 (0.62-5.88) 0.26
TG＋GG 38 (74.5)  31 (45.6) 0.27 (0.12-0.61) 0.002 35 (58.3) 47 (59.5) 1.11 (0.56-2.22) 0.76
T 58 (56.9) 102 (75.0) 1.00 79 (65.8) 97 (61.4) 1.00
G 44 (43.1)  34 (25.0) 0.44 (0.25-0.76) 0.004 41 (34.2) 61 (38.6) 1.25 (0.75-2.08) 0.39
†Adjusted for age,  smoking status and alcohol use in a logistic regression model
many speciﬁc polymorphisms,  which were thought to 
be associated with aging and with the risk of myocar-
dial infarction,  osteoporosis and breast cancer [9,  
11-14].  For Leu1074Phe,  one of the most common 
missense SNPs in WRN,  many previous studies also 
revealed its association with various diseases.  A study 
involving Finnish and Mexican populations reported an 
age-dependent decline of the 1074Phe/Phe genotype,  
suggesting a beneﬁcial eﬀect of the Leu allele in aging 
populations [9].  Two studies have addressed the 
relationship of WRN Leu1074Phe with breast cancer,  
but with diﬀerent results.  Wang Z et al. [11] reported 
a signiﬁcant association of the WRN 1074 Phe/Phe 
genotype with breast cancer risk in Chinese women 
(OR＝1.36,  95ｵCI: 1.06-1.74) and a 3.58-fold 
increased risk of breast cancer (OR＝3.58,  95ｵ
CI: 2.54-5.05) for subjects carrying the TT genotype 
and with earlier menarche at the same time.  Another 
case-control study of 935 primary breast cancer 
patients and 1,545 healthy controls revealed that WRN 
Leu1074Phe was not associated with the risk of 
breast cancer in Taiwanese females [15].  Studies of 
the association with other cancers are rare.  A recent 
large population-based case-control study failed in 
ﬁnding a signiﬁcant association with the risk of col-
orectal cancer in a German population [16].
　 In the present study,  we discussed the polymor-
phism WRN Leu1074Phe and PCa susceptibility in a 
relatively small sample of Chinese men.  Similar to 
previous results obtained for East Asian people from 
HapMap and Taiwanese females,  we observed a sig-
niﬁcantly lower proportion of G alleles compared with 
T alleles in Chinese men.  This was in contrast to 
studies performed on Caucasian populations,  which 
showed a relative predominance of G alleles (Table 7,  
Ref. 11,  15-17).  However,  our genotyping results 
seem to be diﬀerent than those of Wang Z et al. [11],  
who detected a predominance of G alleles in Chinese 
women.  This confusing phenomenon might be 
explained by gender and geographic diﬀerences.  
　 We examined the putative impact of the WRN 
Leu1074Phe genotype and found a signiﬁcant associa-
tion with the risk of prostate cancer in a Chinese 
population,  suggesting that the eﬀect of WRN 
Leu1074Phe on prostate cancer risk might be strongly 
evident in Chinese men.  In a study by Kamath-Loeb 
and colleagues [10],  a small decrease in helicase and 
exonuclease (about 1/3 in quantiﬁcation) was found 
for variant protein 1074Phe/Phe compared to the 
wild-type protein 1074Leu,  indicating that the latter 
had a higher repair capacity and thus was more beneﬁ-
cial for sustaining the stability of the genome.  The 
results of the present study showed that the Leu＋ 
(G＋) genotypes had signiﬁcant protective eﬀects 
against the risk of prostate cancer; these results were 
consistent with those of Kamath-Loeb [10].
　 In contrast with previous studies [18,  19],  we 
chose 72 years of age as the dividing line for an anal-
ysis stratiﬁed by diﬀerent diagnosis age.  The purpose 
for choosing age 72 was to make the number of cases 
as equal as possible between the older and younger 
subgroups.  Finally,  a signiﬁcant association was noted 
in subjects with an early diagnosis age (ｦ72),  but not 
in subjects with a later diagnosis age (＞72).  This 
indicated that the polymorphism WRN Leu1074Phe 
might play an important role in promoting the early 
onset of the disease.  
　 Moreover,  when stratifying the case group by the 
aggressiveness of the disease,  the present study found 
that WRN Leu1074Phe was signiﬁcantly associated 
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Table 7　 Reported WRN Leu1074Phe genotype frequencies [n (％)] in normal control subjects from diﬀerent ethnic groups
Study group n
Genotype (％) Allele (％)
Ref.GG GT TT G T
HapMap-CEU  120 36.7 36.7 26.7 55.0 45.0
HapMap-HCB   90 17.8 55.6 26.7 45.6 54.4
HapMap-JPT   90 11.1 40.0 48.9 31.1 68.9
German 1,780 35.0 46.6 18.4 58.3 41.7 (16)
Chinese female 1,008 38.9 44.7 16.4 61.3 38.7 (11)
Taiwanese female 1,538 11.5 46.8 41.7 34.9 65.1 (15)
Chinese  139 12.9 48.9 38.1 37.4 62.6 (17)
Chinese male, present study  111 10.8 55.0 34.2 38.3 61.7
with localized prostate cancer,  but not with advanced 
disease.  We also observed that localized subjects had 
a lower distribution frequency of the protective geno-
type TG/GG compared with advanced subjects (Table 
6).  This result was interesting when compared with 
those of other studies [18,  20],  in which the correla-
tions between SNPs and cancers were usually more 
signiﬁcant in advanced diseases than localized ones.  
One possible explanation was that the genetic variant 
WRN Leu1074Phe may not play an important role in 
the progression and metastasis of prostate 
cancer; another possible explanation was that the 
number of cases in our subgroup analysis was rela-
tively small,  and its power to explain the diﬀerences 
was limited.  The third possible explanation was that 
there was no routine screening of the PSA level for 
people older than 50 or 60 years in China,  and in 
some of our case subjects the diseases were already 
advanced when they were initially diagnosed.  This 
might have caused localized and advanced diseases to 
be mixed to a certain extent.  Except for the aggres-
siveness,  no other clinical characteristics such as 
Gleason score,  PSA level at diagnosis or age at 
diagnosis were found to be associated with WRN 
Leu1074Phe.  Interactions between the polymorphism 
and other potential risk factors,  such as smoking and 
drinking status,  were also assessed in this study.  
However,  no positive result was found,  as shown in 
Table 6.
　 Several limitations existed in our case-control 
study.  Firstly,  the sample size may limit the statisti-
cal power of our study,  especially for subgroups with 
diﬀerent diagnosis ages and levels of aggressiveness.  
Secondly,  our prostate cancer patients were from 
hospitals and the controls were randomly selected 
from among cancer-free patients in these same hospi-
tals,  so whether they formed a representative control 
population needs to be assessed.
　 In conclusion,  our study indicated that the single 
nucleotide polymorphism WRN Leu1074Phe was sig-
niﬁcantly associated with prostate cancer risk in 
Chinese men,  suggesting that it may be a useful bio-
marker of the predisposition for prostate cancer.  
Larger well-designed studies with suﬃcient explana-
tory power are needed to conﬁrm our ﬁndings.
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